October 27, 2020 -- Genome & Company has initiated clinical testing of GEN-001, an anti-cancer microbiome therapeutic, six months after its investigational new drug approval.
The phase Ib clinical trial will evaluate the oral microbiology therapy candidate in combination with avelumab (Bavencio), an anti-programmed cell death ligand 1 (PD-L1) checkpoint inhibitor in patients with a variety of solid tumors. Bavencio is being jointly developed by Merck and Pfizer.
A total of three trial centers including Oregon Health and Science University Knight Cancer Institute will complete the dose escalation cohort in the first half of 2021.
Under the agreement, Genome & Company will sponsor the study and Merck and Pfizer will supply Bavencio for the phase I/IB clinical trial.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
